Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: .
作者信息
Subbiah Vivek, Kurzrock Razelle
机构信息
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
J Clin Oncol. 2023 Jun 10;41(17):3100-3103. doi: 10.1200/JCO.22.02833. Epub 2023 Mar 17.
Abstract
摘要
相似文献
1
Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: .战胜癌症需要进行全面的生殖系和肿瘤基因组检测：
J Clin Oncol. 2023 Jun 10;41(17):3100-3103. doi: 10.1200/JCO.22.02833. Epub 2023 Mar 17.
2
Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis.战胜癌症需要进行全面的基因组检测：基因组学即诊断。
JAMA Oncol. 2016 Jun 1;2(6):719-20. doi: 10.1001/jamaoncol.2016.0078.
3
Tumor Genomic Testing: Identifying Characteristics Associated With Germline Risk for Developing Malignancy.肿瘤基因组检测：鉴定与遗传性恶性肿瘤风险相关的特征。
Clin J Oncol Nurs. 2020 Dec 1;24(6):623-626. doi: 10.1188/20.CJON.623-626.
4
"Somatic" Tumor Genomic Profiling and Potential Germline Implications: Ethical Considerations for Children with Cancer.“体细胞”肿瘤基因组分析及潜在的种系影响：癌症患儿的伦理考量
J Law Med Ethics. 2020 Dec;48(4):778-783. doi: 10.1177/1073110520979389.
5
Tumor genome analysis includes germline genome: are we ready for surprises?肿瘤基因组分析包括种系基因组：我们准备好迎接意外了吗？
Int J Cancer. 2015 Apr 1;136(7):1559-67. doi: 10.1002/ijc.29128. Epub 2014 Aug 14.
6
When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?肿瘤基因组分析检测结果何时提示应考虑胚系基因检测？
J Oncol Pract. 2019 Sep;15(9):465-473. doi: 10.1200/JOP.19.00201.
7
The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?平行肿瘤和种系遗传检测的未来：所有癌症患者都有必要进行检测吗？
J Natl Compr Canc Netw. 2021 Jul 28;19(7):871-878. doi: 10.6004/jnccn.2021.7044.
8
Most patients with cancer are not undergoing germline genetic testing.大多数癌症患者未接受种系基因检测。
CA Cancer J Clin. 2024 Jan-Feb;74(1):6-7. doi: 10.3322/caac.21827.
9
Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer.采用通用基因检测识别癌症患者的致病性种系变异
JAMA Oncol. 2021 Jul 1;7(7):1071. doi: 10.1001/jamaoncol.2021.1005.
10
Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer.通过全基因组检测识别癌症患者的致病性种系变异
JAMA Oncol. 2021 Jul 1;7(7):1070. doi: 10.1001/jamaoncol.2021.1002.
引用本文的文献
1
Critical evaluation of the ProfiLER-02 study design and outcomes.对ProfiLER-02研究设计与结果的批判性评估。
Nat Med. 2025 Sep 10. doi: 10.1038/s41591-025-03959-2.
2
Screening and Identification of a Common Haplotype in the Jewish Community of Rome Reveal a Founder Effect for the c.7007G>C, p. (Arg2336Pro) Variant.罗马犹太社区常见单倍型的筛选与鉴定揭示了c.7007G>C，p.（Arg2336Pro）变异的奠基者效应。
Cancers (Basel). 2025 Jun 8;17(12):1906. doi: 10.3390/cancers17121906.
3
Hereditary Hematopoietic Malignancies: Considerations for Optimizing Diagnosis and Management.遗传性造血系统恶性肿瘤：优化诊断与管理的考量因素
Curr Oncol Rep. 2025 Jun 26. doi: 10.1007/s11912-025-01699-7.
4
Tissue-agnostic cancer therapies: promise, reality, and the path forward.组织非特异性癌症疗法：前景、现状与未来之路。
Nat Commun. 2025 May 29;16(1):4972. doi: 10.1038/s41467-025-60369-1.
5
Cancer treatment paradigms in the precision medicine era.精准医学时代的癌症治疗模式。
Nat Med. 2025 May 20. doi: 10.1038/s41591-025-03711-w.
6
Health Care Equity and Testing.医疗保健公平性与检测
Health Equity. 2025 Feb 21;9(1):127-130. doi: 10.1089/heq.2024.0167. eCollection 2025.
7
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations.早发性与平均发病年龄结直肠癌人群的基因组图谱
Cancers (Basel). 2025 Feb 28;17(5):836. doi: 10.3390/cancers17050836.
8
Tumour-agnostic kinase inhibitors.肿瘤非特异性激酶抑制剂。
Nat Rev Drug Discov. 2025 Mar 6. doi: 10.1038/s41573-025-01147-y.
9
Novel clinical trial designs emerging from the molecular reclassification of cancer.源于癌症分子重新分类的新型临床试验设计。
CA Cancer J Clin. 2025 May-Jun;75(3):243-267. doi: 10.3322/caac.21880. Epub 2025 Jan 22.
10
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.将通用种系基因检测纳入前列腺癌患者的标准治疗：时机已到。
JCO Oncol Pract. 2025 Jun;21(6):747-753. doi: 10.1200/OP-24-00626. Epub 2024 Dec 19.
本文引用的文献
1
A refined use of mutations to guide immunotherapy decisions.一种利用突变来精准指导免疫治疗决策的方法。
Nature. 2022 Dec;612(7941):639-641. doi: 10.1038/d41586-022-04448-z.
2
Characterization of Oncology Clinical Trials Using Germline Genetic Data.基于胚系遗传数据的肿瘤临床试验特征分析。
JAMA Netw Open. 2022 Nov 1;5(11):e2242370. doi: 10.1001/jamanetworkopen.2022.42370.
3
Accelerated approvals hit the target in precision oncology.加速批准在精准肿瘤学领域命中目标。
Nat Med. 2022 Oct;28(10):1976-1979. doi: 10.1038/s41591-022-01984-z.
4
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.基于祖源的肿瘤突变负荷重新校准与免疫检查点抑制剂反应的不同临床结局。
Cancer Cell. 2022 Oct 10;40(10):1161-1172.e5. doi: 10.1016/j.ccell.2022.08.022. Epub 2022 Sep 29.
5
Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.乳腺癌患者进行通用种系基因检测的临床实用性。
JAMA Netw Open. 2022 Sep 1;5(9):e2232787. doi: 10.1001/jamanetworkopen.2022.32787.
6
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer.实体肿瘤癌症患者遗传性癌症综合征的通用种系基因检测
JCO Precis Oncol. 2022 Sep;6:e2100516. doi: 10.1200/PO.21.00516.
7
Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects.当前遗传性癌症综合征的系统性治疗：基于基因组缺陷的药物研发。
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-17. doi: 10.1200/EDBK_350232.
8
Paired Tumor-Germline Testing as a Driver in Better Cancer Care.配对肿瘤-胚系检测作为改善癌症治疗的推动因素
JAMA Netw Open. 2022 May 2;5(5):e2213077. doi: 10.1001/jamanetworkopen.2022.13077.
9
Think Globally, Act Locally: Globalizing Precision Oncology.放眼全球，立足本地：精准肿瘤学全球化。
Cancer Discov. 2022 Apr 1;12(4):886-888. doi: 10.1158/2159-8290.CD-22-0024.
10
Disparities in germline testing among racial minorities with prostate cancer.前列腺癌少数族裔人群中种系检测的差异。
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):403-410. doi: 10.1038/s41391-021-00469-3. Epub 2021 Nov 13.
Zotero 插件